CAJ | 학술논문

恶性胸腔积液是晚期非小细胞肺癌常见并发症，严重影响肿瘤患者生活质量。重组人血管内皮抑素注射液（恩度）自2006年国家食品药品监督管理局批准上市以来，其与顺铂联合行胸腔内灌注治疗非小细胞肺癌合并恶性胸腔积液的患者，取得了值得肯定的疗效，且安全性较好。本文回顾了近年恩度联合顺铂方案胸腔内灌注治疗非小细胞肺癌恶性胸腔积液的文献，就其最新进展进行综述。
악성흉강적액시만기비소세포폐암상견병발증，엄중영향종류환자생활질량。중조인혈관내피억소주사액（은도）자2006년국가식품약품감독관리국비준상시이래，기여순박연합행흉강내관주치료비소세포폐암합병악성흉강적액적환자，취득료치득긍정적료효，차안전성교호。본문회고료근년은도연합순박방안흉강내관주치료비소세포폐암악성흉강적액적문헌，취기최신진전진행종술。
Malignant pleural effusion ( MPE ) is a common complication of advanced non -small cell lung cancer ( NSCLC) and has seriously impacts on patient's quality of life.Recombinant human endostatin injection ( Endostar) , SF-DA approved since 2006, combined with cisplatin intrapleural perfusion showed good effectivity and good safety for the treatment of NSCLC patients with MPE.The recent clinical research of Endostar combined with cisplatin intrapleural perfu-sion for the treatment of NSCLC MPE are reviewed.